刺
癌症研究
干扰素基因刺激剂
信号转导
干扰素
免疫系统
化学
肿瘤微环境
免疫疗法
细胞生物学
生物
先天免疫系统
免疫学
工程类
航空航天工程
作者
Wen‐Cheng Xu,Luying Qiao,Zhifang Wang,Yanrong Qian,Lei Li,Qianqian Sun,Chunxia Li
标识
DOI:10.1016/j.cej.2023.145702
摘要
The cyclic-GMP-AMP synthetase stimulator of interferon genes (cGAS-STING) pathway is a naturally occurring immune pathway activated by cytosolic DNA. The end products of this pathway are type I interferon (type I IFN) and multiple cytokines, which have been utilized to carry out anti-tumor therapy in recent years. However, human embryonic growth factor receptor-2 (HER2), which is highly expressed in a variety of tumor cells, can inhibit the cGAS-STING pathway through phosphorylation, seriously interfering with the normal expression of this pathway. Therefore, if HER2 inhibition is not taken into account when activating the cGAS-STING pathway, the effectiveness of the STING pathway will be greatly reduced. Herein, we developed a nanosystem hMnOx-LPT@BSA (HMLB) with STING pathway activation for overcoming tumor suppression and enhancing immune response. In the presence of glutathione (GSH), honeycomb MnOx (hMnOx, HM) degraded and released a large amount of Mn2+, which could not only produce reactive oxygen species (ROS) to kill tumor cells through a Fenton-like reaction but also bind to STING pathway components to improve cytosolic DNA detection. In response to the high expression of HER2 in tumor cells, the HER2-specific inhibitor Lapatinib (LPT) was introduced to promote cGAS-STING pathway-based immunotherapy together with Mn2+. The synergistic effect of the dual approach activation of the STING pathway and Mn2+-dependent chemodynamic therapy (CDT) could achieve the goals of inhibiting tumor growth and inducing immune responses. Therefore, we believe that this therapeutic strategy has a promising potential for further clinical translation.
科研通智能强力驱动
Strongly Powered by AbleSci AI